Wednesday, July 8, 2026

biotech · Blepharitis · Meibomian Gland Dysfunction · TARS

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

15440 Laguna Canyon Rd, Irvine, California 92618, US HQ
2017 Founded
403 Employees
Public company Type
TARS · NYSE Ticker
Company details
Status
Public
HQ
15440 Laguna Canyon Rd, Irvine, California 92618, US
Founded
2017
Employees
403
Programs
14
Drugs
10
Patents
9
Intelligence · Clinical Programs

Tarsus Pharmaceuticals projects

3 ClinicalTrials.gov programs sponsored by Tarsus Pharmaceuticals.

Tarsus Pharmaceuticals has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. TP-03 (Lotilaner Ophthalmic Solution), 0.25%

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial
  2. TP-05 (lotilaner oral capsules)

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial
  3. TP-05 (lotilaner oral), fasted group

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Tarsus Pharmaceuticals have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.